Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient

Annals of Saudi Medicine

Volumn 30, Issue 5, 2010, Pages 404-407

  Al Qadheeb, Nada ^a   Althawadi, Sahar ^a   Alkhalaf, Abdulaziz ^a   Hosaini, Suleiman ^a   Alrajhi, Abdulrahman ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CARBAPENEM DERIVATIVE; COLISTIN; HYPERTENSIVE FACTOR; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPIRATION PNEUMONIA; BACTERIUM ISOLATION; BLOOD CULTURE; CASE REPORT; CHRONIC KIDNEY FAILURE; COLITIS; COMMUNITY ACQUIRED PNEUMONIA; COUGHING; DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EXTUBATION; FEVER; FUNGUS CULTURE; GRAM NEGATIVE BACTERIUM; HEART FAILURE; HUMAN; HYPOTENSION; INTENSIVE CARE; INTUBATION; KLEBSIELLA PNEUMONIAE INFECTION; LEUKOCYTE COUNT; LUNG INFILTRATE; MALE; NOCARDIOSIS; OXYGENATION; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS; PSEUDOMONAS INFECTION; RENAL REPLACEMENT THERAPY; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REST; SEPTIC SHOCK; THORAX RADIOGRAPHY; TOXOPLASMOSIS; TREATMENT RESPONSE; VOMITING;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FATAL OUTCOME; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MINOCYCLINE;

EID: 77956252770     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.4103/0256-4947.67087     Document Type: Article

References (23)

1. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: Molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56:128-32.
2. Ahmad S, Al-Juaid NF, Alenzi FQ, Mattar EH, Bakheet Oel S. Prevalence, antibiotic susceptibility pattern and production of extended-spectrum beta-lactamases amongst clinical isolates of Klebsiella pneumoniae at Armed Forces Hospital in Saudi Arabia. J Coll Physicians Surg Pak 2009;19:264-5.
3. Al-Agamy MH, Shibl AM, Tawfik AF. Prevalence and molecular characterization of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in Riyadh, Saudi Arabia. Ann Saudi Med 2009;29:253-7.
4. Bilal NE, Gedebou M. Clinical and community strains of Klebsiella pneumoniae: Multiple and increasing rates of antibiotic resistance in Abha, Saudi Arabia. Br J Biomed Sci 2000;57:185-91.
5. El-Khizzi NA, Bakheshwain SM. Prevalence of extended-spectrum beta-lactamases among Enterobacteriaceae isolated from blood culture in a tertiary care hospital. Saudi Med J 2006;27:37-40.
6. Kader AA, Angamuthu K. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia. Saudi Med J 2005;26:956-9.
7. Kader AA, Kumar A. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital. Ann Saudi Med 2005;25:239-42.
8. Kader AA, Kumar AK. Prevalence of extended spectrum beta-lactamase among multidrug resistant gram-negative isolates from a general hospital in Saudi Arabia. Saudi Med J 2004;25:570-4.
9. Khanfar HS, Bindayna KM, Senok AC, Botta GA. Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: Trends in the hospital and community settings. J Infect Dev Ctries 2009;3:295-9.
10. Memon JI, Rehmani RS, Ahmed MU, Elgendy AM, Nizami IY. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia. Saudi Med J 2009;30:803-8.
11. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-36.
12. Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007;27:1052-7.
13. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005;49:4423-4.
14. Moland ES, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson KS. Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob Agents Chemother 2002;46:3837-42.
15. Smith Moland E, Hanson ND, Herrera VL, Black JA, Lockhart TJ, Hossain A, et al. Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 2003;51:711-4.
16. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 2009;30:1180-5.
17. Giske C, Monnet D, Cars O, Carmeli Y. Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli. Antimicrob Agents Chemother 2008;3:813-21.
18. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review. Lancet Infect Dis 2010;10:43-50.
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI document M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
20. Gautom RK. Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol 1997;35:2977-80.
21. Hawser SP, Bouchillon SK, Hoban DJ, Hackel M, Johnson JL, Badal RE. Klebsiella pneumoniae isolates possessing KPC beta-lactamase in Israel, Puerto Rico, Colombia and Greece. Int J Antimicrob Agents 2009;34:384-5.
22. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-70.
23. CDC. Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities. MMWR Morb Mortal Wkly Rep 2009;58:256-60.